Allen Wealth Management LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

Allen Wealth Management LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 87,236 shares of the biopharmaceutical company's stock after selling 11,703 shares during the period. Pfizer makes up 1.7% of Allen Wealth Management LLC's holdings, making the stock its 11th biggest holding. Allen Wealth Management LLC's holdings in Pfizer were worth $2,314,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. PSI Advisors LLC boosted its holdings in Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after acquiring an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. boosted its holdings in Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 391 shares during the last quarter. Lipe & Dalton increased its stake in Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC increased its stake in Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after buying an additional 401 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Pfizer Stock Performance

Shares of PFE stock traded down $0.41 during trading on Thursday, reaching $24.30. 53,412,700 shares of the company's stock traded hands, compared to its average volume of 39,310,365. The firm's 50-day moving average is $25.93 and its 200 day moving average is $26.81. The company has a market capitalization of $137.79 billion, a P/E ratio of 17.23, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1 year low of $24.26 and a 1 year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue for the quarter was up 24.7% on a year-over-year basis. During the same period last year, the company earned $0.10 earnings per share. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Bank of America restated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Finally, Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.